Results 101 to 110 of about 239,372 (260)
Catheterization and Cardiovascular Interventions, EarlyView.ABSTRACT Background Adverse events after acute myocardial infarction (AMI) are individually associated with poor outcomes, but the prognostic impact of the overlap of different event types occurring sequentially within the same patient remains uncertain.
Kyung Hoon Roh +12 more
wiley +1 more source
Chronic Diseases and Translational Medicine, EarlyView.Nonlinear associations of serum sodium levels with cardiovascular (A) and all‐cause mortality (B)among 32,837 adults. Nonlinear associations of serum potassium levels with cardiovascular (C) and all‐cause mortality (D) among 32,837 adults. ABSTRACT Background This study aimed to investigate the associations of serum sodium and potassium levels within ...
Haofeng Zhang +7 more
wiley +1 more source
Direct measurement of LDL cholesterol [PDF]
Clinical Chemistry, 1996 S S, Levinson, J J, Maciejko
openaire +2 more sources
Boron Neutron Capture Therapy at a Crossroads: Translational Gap and Emerging Delivery Agents
Chemistry – A European Journal, EarlyView.This review surveys recent advances in boron delivery agents for BNCT, emphasizing the shift from classical small molecules to multifunctional nanocarriers and theranostic systems. By integrating targeting, imaging, and therapy, next‐generation boron compounds aim to bridge the gap between (bio)chemical innovation and clinical translation.
Christoph Selg, Evamarie Hey‐Hawkins
wiley +1 more source
Clinical Pharmacology &Therapeutics, EarlyView.Carfilzomib is highly effective in the treatment of multiple myeloma, but it has been associated with cardiovascular adverse events that impact patient outcomes. Our prior global metabolomic analyses indicated an association between hydrophilic bile acids and carfilzomib‐cardiotoxicity risk, although a causal relationship remained to be determined ...
Samia Shabnaz +15 more
wiley +1 more source
Clinical Pharmacology &Therapeutics, EarlyView.Traditionally, clinical outcomes measuring how a patient feels, functions, or survives are preferred endpoints in clinical trials; however, some may take a long time to manifest in slowly developing diseases. Biomarkers, if properly validated, can serve as surrogate endpoints, acting as substitutes for clinical outcomes.
Renske Johanna Grupstra +4 more
wiley +1 more source
Clinical Pharmacology &Therapeutics, EarlyView.Proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (mAbs) lower LDL cholesterol and may influence cancer through immunomodulatory pathways. However, their effect on human cancer incidence remains unknown. We conducted a retrospective, propensity score‐matched study (Clalit Health Services, Israel, 2010–2023) comparing PCSK9 ...
Inbar Nardi Agmon +10 more
wiley +1 more source
Systemic aging fuels heart failure: Molecular mechanisms and therapeutic avenues
ESC Heart Failure, Volume 12, Issue 2, Page 1059-1080, April 2025.Abstract Systemic aging influences various physiological processes and contributes to structural and functional decline in cardiac tissue. These alterations include an increased incidence of left ventricular hypertrophy, a decline in left ventricular diastolic function, left atrial dilation, atrial fibrillation, myocardial fibrosis and cardiac ...
Zhuyubing Fang +7 more
wiley +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 1141-1150, April 2025.Abstract Background Arterial stiffness is a crucial factor in determining an increase in systolic blood pressure and pulse pressure and can also predict the development of cardiovascular disease (CVD). The purpose of this study was to examine the relationship between arterial stiffness and future CVD.
Susan Darroudi +10 more
wiley +1 more source